



Synthetic Biologics, Inc.
9605 Medical Center Drive, Suite 270
Rockville, Maryland 20850

May 14, 2018

VIA EDGAR

United States Securities
and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Ms. Dorrie Yale

Re: Synthetic Biologics, Inc.
Registration Statement on Form S-3
File No: 333-224728

Ladies and Gentlemen:

Synthetic Biologics, Inc. (the “**Registrant**”) hereby requests that the United States Securities and Exchange Commission (the “**Commission**”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-22478), to become effective on **Tuesday, May 15, 2018**, at **4:00 p.m.**, Eastern Time, or as soon thereafter as is practicable.

The Registrant hereby authorizes its counsel, Leslie Marlow, Esq. of Gracin & Marlow, LLP, to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (516) 496-2223 or (212) 907-6457 with any questions you may have concerning this request, and please notify her when this request for acceleration has been granted.

Very truly yours,

Synthetic Biologics, Inc.

By: /s/ Steven A. Shallcross
Name: Steven A. Shallcross
Title: Interim Chief Executive Officer and
Chief Financial Officer

cc: Leslie Marlow, Esq., Gracin & Marlow, LLP
